Blood-Based Biomarkers for Pulmonary Nodule Risk Stratification

Blood-based biomarker assays show promise as adjunctive tools for pulmonary nodule management, particularly for excluding malignancy and potentially reducing unnecessary invasive procedures. Fragmentomics platforms demonstrated the most consistent performance, but further large-scale prospective studies are needed to address outstanding questions as clinical applications expand.